LGD 2941

Drug Profile

LGD 2941

Alternative Names: LGD-2226; LGD-2941; LGD122941

Latest Information Update: 24 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Aminoquinolines; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cachexia; Female sexual dysfunction; Hypogonadism; Male sexual dysfunction; Menopausal syndrome; Osteoporosis

Most Recent Events

  • 18 Jun 2008 Pharmacokinetics and adverse events data from a Phase-I trial in healthy volunteers presented at the 90th Annual Meeting of the Endocrine Society (ENDO-2008)
  • 11 Oct 2007 Preclinical data added to the Musculoskeletal Disorders and Women's Health pharmacodynamics sections
  • 11 Sep 2007 Phase I development is ongoing in Osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top